Cargando…
Comparison and discussion of the treatment guidelines for small cell lung cancer
Small cell lung cancer (SCLC), which accounts for 15% to 17% of all lung cancers, is one of the leading causes of cancer‐related death worldwide. More than 130 000 new diagnoses of SCLC and 100 000 deaths from the disease were estimated to have occurred in China in 2013. The existing guidelines of S...
Autores principales: | Zhao, Honglin, Ren, Dian, Liu, Hongyu, Chen, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026606/ https://www.ncbi.nlm.nih.gov/pubmed/29770597 http://dx.doi.org/10.1111/1759-7714.12765 |
Ejemplares similares
-
KRAS oncogene may be another target conquered in non‐small cell lung cancer (NSCLC)
por: Chen, Hanxiao, et al.
Publicado: (2020) -
Recent advances in neoantigen vaccines for treating non‐small cell lung cancer
por: Su, Shu, et al.
Publicado: (2023) -
Role of acetylcholinesterase in lung cancer
por: Xi, Hui-Jun, et al.
Publicado: (2015) -
Immunotherapy in Cancer Management: A Literature Review of Clinical Efficacy of Pembrolizumab in the Non-small Cell Lung Cancer Treatment
por: Miquelotti, Luísa Biscaglia, et al.
Publicado: (2023) -
Role of long non‐coding RNA in drug resistance in non‐small cell lung cancer
por: Wang, Leirong, et al.
Publicado: (2018)